Universal Registration Document

Overview

The report describes the company as a clinical-stage biopharmaceutical developer focused on first-in-class treatments for major central nervous system disorders. In 2023, AEF0117 phase 2b enrollment reached 333 patients, while regulatory non-clinical studies were completed to prepare for phase 3. The company also continued its environmental-impact review and implemented measures to extend IT-equipment life and promote repair, reuse or recycling.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 24 April 2024
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services